



Commercial Momentum and Pipeline Progress June 2026

ASX:CBL

About Us

Control Bionics Limited (ASX: CBL) ("Control Bionics" or "the Company"), a global neurotechnology company commercialising non-invasive neural-signal technology, is pleased to provide stakeholders with an update on the significant progress the business has made in building customer relationships and commercial pathways across its three strategic pillars:

- Assistive Technology
- NeuroTech Solutions
- Platform and Medical Technologies

Control Bionics' strategy is focused on scaling a single underlying neural-signal technology platform across multiple commercial markets. The Company's core technology captures the body's electrical signals generated by muscles and converts those signals into actionable data. This technology has historically been deployed in assistive communication through the NeuroNode, and is now being extended into sports performance, rehabilitation, medical research, platform partnerships and broader human-computer interface applications.

The Company's recent customer activity demonstrates growing validation of this strategy. Across assistive communication, rehabilitation, elite sport and research partnerships, Control Bionics is building a broader customer base and expanding the commercial use cases for its proprietary surface electromyography (sEMG) technology.





Assistive Technology

Assistive Technology

Control Bionics' Assistive Technology business continues to provide the commercial foundation for the Company, with the NeuroNode remaining a differentiated access technology for people with complex communication and physical needs.

The Company continues to receive strong validation from insurers, clinicians, distribution partners and customers following the award of the dedicated E2513 HCPCS code for the NeuroNode in the United States. US states representing almost 70% of the US population have now funded the NeuroNode through the HCPCS code pathway. Funding to date has been represented by Medicare, commercial insurance and Medicaid, with claims activity currently estimated at approximately 55% Medicare, 35% commercial insurance and 10% Medicaid.

This is a significant development for Control Bionics. A dedicated reimbursement pathway provides a stronger structural foundation for NeuroNode adoption in the United States and supports the Company's transition from a direct retail sales model to a scalable wholesale distribution model.



Assistive Technology

Tobii Dynavox

Following the signing of Control Bionics' initial US five-state agreement with Tobii Dynavox, the CBL team has completed onboarding and training activities, and first funded sales from Tobii have commenced.

The initial focus has been on ensuring Tobii's teams and customers are supported through the early sales and implementation process. Control Bionics expects to engage with Tobii in June 2026 to commence planning for rollout into additional US states.

PRC-Salttillo

Control Bionics signed a US-wide distribution agreement with PRC-Salttillo in January 2026. Funded sales have already commenced, and the Company is working with PRC-Salttillo on plans for broader activation across its sales organisation.

PRC-Salttillo's full sales team, comprising approximately 70 sales representatives, is expected to commence broader rollout activity in the late US summer of 2026.

Assistive Technology

New York Board of Education

Control Bionics has entered into a long-term supply agreement with the New York Board of Education for the NeuroNode.

This agreement is strategically important as it provides an established purchasing pathway for the NeuroNode and will also be utilised by Control Bionics' US distribution partners.

NextLeveliOS Tablets


In April 2026, Control Bionics signed a Letter of Intent with a launch customer for the supply of iOS-based speech generating devices. The Letter of Intent contemplates 1,000 devices in the first 12 months, and the Company has received a US\$100,000 advance payment.

Devices are expected to commence shipping in July 2026. This initiative is expected to expand the Company's product offering, increase distributor relevance and support Control Bionics' broader strategy of providing scalable assistive communication solutions through partner-led channels.

Germany

The NeuroNode was awarded HMV insurance coverage in Germany in February 2026. This provides a new reimbursement pathway in one of Europe's most important healthcare markets.

Control Bionics is currently in discussions with multiple potential German distribution partners to support the rollout of the NeuroNode in the German market.




NeuroTech Solutions

NeuroTech Solutions

Control Bionics' NeuroTech Solutions pillar is focused on applying the Company's proprietary sEMG technology through NeuroStrip in sports performance, return-to-play assessment, athlete profiling, rehabilitation and clinical use cases.

NeuroStrip is a lightweight, wearable sEMG platform designed to capture muscle activation data in real-world environments such as gyms, clinics, training fields and rehabilitation settings. The customer activity currently underway across Australia and the United States provides early evidence of the breadth of use cases for the platform.



Australia

Sport Teams

Control Bionics is currently engaged with numerous leading Australian sporting and rehabilitation organisations to assess the use of NeuroStrip in athlete rehabilitation, return-to-play decision making, player profiling and clinical rehabilitation – these include:

Sydney-based AFL team

Control Bionics is working with a Sydney-based AFL team on return-to-play and player profiling applications. The initial engagement is structured as a three-month trial and is focused on assessing how NeuroStrip can provide objective neuromuscular data to support athlete management and performance decisions.

Melbourne-based AFL team

Control Bionics is engaged with a Melbourne-based AFL team on return-to-play applications. The initial engagement is structured as a four-month trial and will assess the use of NeuroStrip in supporting rehabilitation and athlete readiness decisions.

Queensland-based Rugby League team

Control Bionics is engaged with a Queensland-based rugby league team to assess the use of NeuroStrip in return-to-play decision making. The initial engagement is structured as a three-month trial.

Australia

Organisations



Australian national governing body for a major winter sport

Control Bionics is engaged with an Australian national governing body for a major winter sport. The initial engagement is structured as a three-month trial and is focused on return-to-play applications.

Australian Institute of Sport

Control Bionics is undertaking an initial trial with the Australian Institute of Sport utilising NeuroStrip in athlete rehabilitation. The AIS engagement is an important validation opportunity for the Company as it seeks to demonstrate the practical application of objective sEMG data in elite athlete environments.

Royal Rehab

Control Bionics is engaged with Royal Rehab on an initial three-month trial assessing the use of NeuroStrip in both clinical and at-home settings. Royal Rehab has more than 50 locations across Australia. This trial is aligned with the Company's objective of expanding NeuroStrip beyond elite sport into rehabilitation and broader clinical pathways.

International

Sport

Control Bionics' technology has had interest from beyond our core markets of the US and Australia. The business is actively engaged with a number of international sports groups – these include:

Major International Football (soccer) club

A Control Bionics team is currently in Europe working with a well-known football club who is actively pursuing the use of sEMG in their franchise.

International Rugby Federation

Control Bionics will onboard this group in mid-June who will use the NeuroStrip for performance, profiling and return to play applications.

International Rugby League team

Control Bionics is engaged with an international league team who intend to use the NeuroStrip for player readiness assessments.

United States

The United States remains a key market for Control Bionics' NeuroTech Solutions business, with activity underway across both sport and rehabilitation.

Sport

Ohio University

Multiple projects are underway with Ohio University, including:

- 500+ athlete profiling as part of athlete concussion protocols;
- up to approximately 100 general population baseline sEMG assessments; and
- basketball applications utilising NeuroStrip to assess muscle activity during strength training.

These projects are designed to assess how objective sEMG data can support athlete profiling, baseline assessment, injury risk insights and performance applications.

Weber State

Control Bionics is engaged with Weber State on sEMG profiling of the entire women's volleyball team. This engagement supports the Company's broader strategy of deploying NeuroStrip into collegiate sport environments where athlete profiling, performance optimisation and return-to-play decision making are key priorities.

NeuroBounce


Control Bionics continues to build customer relationships for NeuroBounce, the Company's sports performance program that combines sEMG feedback with targeted strength and conditioning protocols.

Current NeuroBounce activity includes:

- Weber State;
- Hoops Hall;
- Club V South; and
- Peak Performance.

United States

Rehabilitation



Bay State Physical Therapy

Control Bionics is rolling out NeuroStrip to the first clinic within Bay State Physical Therapy's network. Bay State Physical Therapy represents a significant potential rehabilitation channel, with a network of more than 160 clinics across the United States.

Mayo Clinic

Mayo Clinic has utilised NeuroStrip as part of a study into gait analysis. Mayo Clinic is currently assessing further research options in partnership with Control Bionics, including potential applications for NeuroStrip and the Company's broader sEMG platform.

Penn State Health

Penn State Health is assessing NeuroStrip for use in research applications. This engagement supports Control Bionics' strategy of partnering with leading health and research institutions to evaluate new clinical and research use cases for its technology.

United States



Rehabilitation

Mountain Land Physical Therapy

Control Bionics continues to engage with Mountain Land Physical Therapy, a US rehabilitation and sports performance provider with approximately 70 clinics in the US. Mountain Land is active across rehabilitation and sports performance use cases, and Control Bionics is progressing a case study for its “Super Bridge” application.

“Super Bridge” is a prevention program designed for athletes of all sports above the age of 13 who want to improve their performance and reduce their risk of injury by using EMG biofeedback to firstly detect, then strengthen their muscular weaknesses. It is a 12-session program using the Control Bionics NeuroTech to work on the areas of concern, billed to their insurance with a specific biofeedback code. For the clinic, this means more revenue and more client sessions, as who would typically attend two to three sessions now attend all 12 with the new program offering. Some of the outcomes can be seen below:

\$1175 – \$1375

Revenue Per Client

3 – 9 inches

Improved Jump Height

Up to 15 inches

Increased Lateral Jump

Japan

Rehabilitation

Stroke Lab

Control Bionics is working closely with Stroke Lab in Japan, a specialist neurological rehabilitation clinic dedicated to treating clients with complex neurological conditions.

A patient recovering from a serious brain bleed had been left with significant walking difficulties, repeated stumbling that made independent mobility unsafe and traditional rehabilitation approaches were struggling to pinpoint the exact muscle dysfunction driving the problem. By introducing the Control Bionics NeuroTech, clinicians were able to visualise the over-contraction of the patient's right gastrocnemius in real time, giving them the precision to target the root cause of the instability and adapt treatment as progress was made. The outcomes can be seen below:

163.9 → 99.8 μ V

Gastrocnemius Peak Activity
Reduced

39%

Reduction in Muscle
Overactivity

0 Falls

Post-Intervention Walking Round Trip

This case demonstrates the clinical value of real-time EMG biofeedback in post-stroke gait rehabilitation. By making invisible muscle activity visible, the NeuroTech enabled clinicians at Stroke Lab to target the precise source of gait instability, validate treatment effectiveness objectively, and achieve a meaningful functional outcome





Platform and Medical Technologies



Platform and Medical Technologies

Control Bionics' Platform and Medical Technologies pillar is focused on commercialising the Company's neural-signal platform beyond its current device applications.

This includes technology partnerships, research collaborations, software integrations, data applications, medical technology pathways and broader human-computer interface opportunities.

Apple BCI

Following Control Bionics' agreement to commercialise Apple's BCI protocol, the Company is currently building this capability into the next generation of its software for wide commercial release in Q3 2026.

As previously announced, Apple BCI integration is expected to represent a significant enhancement to customer experience. The integration is also expected to create new potential use cases for Control Bionics' technology outside of the traditional assistive technology market.

The Company believes this integration supports its broader strategic position as a scalable neural-signal platform rather than a single-device company.



Technology and Research Partnerships



Control Bionics has either engaged with, or is in discussions to partner with, a number of leading clinical, research and academic organisations for access to its platform.

These include:

- Mayo Clinic;
- Barrow Neurological Institute;
- Penn State Health;
- University of Sydney;
- Victoria University;
- University of Melbourne; and
- ICCD Partners.

These relationships are expected to support continued validation of the Company's technology, generate new research and clinical use cases, and contribute to the long-term development of Control Bionics' platform and data strategy.

Summary

Control Bionics has made significant progress in recent months across each of its three strategic pillars.

In Assistive Technology, the Company continues to benefit from the dedicated E2513 HCPCS code, increasing funding validation, US distribution partner activation, new iOS tablet opportunities, the New York Board of Education agreement and the opening of the German market through HMV insurance coverage.

In NeuroTech Solutions, the Company is progressing a growing number of sports, rehabilitation and research customer relationships across Australia, the United States and International. These engagements are designed to validate NeuroStrip across athlete profiling, return-to-play, strength training, gait analysis, rehabilitation and at-home clinical applications.

In Platform and Medical Technologies, Control Bionics is progressing Apple BCI integration, research partnerships and broader platform opportunities that have the potential to extend the Company's technology into new markets and new commercial use cases.

Control Bionics remains focused on converting this customer momentum into global scalable commercial outcomes, while continuing to build its position as a leader in non-invasive neural-signal technology.

Authorised for release by the Board of Control Bionics Limited.

Investor and Media Enquiries



Jeremy Steele

CEO & Managing Director

Control Bionics Limited

Email: jsteele@controlbionics.com

Website:

www.controlbionics.com

About Control Bionics

Control Bionics is a global neurotechnology company that captures the body's electrical signals generated by muscles and converts them into actionable data.

The Company's proprietary technology platform is deployed across assistive communication, sports performance, rehabilitation, research and emerging medical technology applications. Control Bionics' products include the NeuroNode and NeuroStrip platforms, which utilise non-invasive surface electromyography and related signal-processing technologies to provide access, insight and control across multiple use cases.

Control Bionics is listed on the Australian Securities Exchange under the code CBL.

Forward-looking statements

This announcement may contain forward-looking statements, including statements regarding anticipated customer activity, product rollout, distribution expansion, research collaborations, commercial opportunities and timing of future releases. Forward-looking statements are based on current expectations and assumptions and are subject to risks and uncertainties, many of which are outside the Company's control. Actual outcomes may differ materially from those expressed or implied in this announcement. The Company does not undertake to update forward-looking statements except as required by law or the ASX Listing Rules.